BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24695331)

  • 1. Perspective: Retreat from the radical.
    Marder SR
    Nature; 2014 Apr; 508(7494):S18. PubMed ID: 24695331
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug research: a plan for mental illness.
    Insel TR; Sahakian BJ
    Nature; 2012 Mar; 483(7389):269. PubMed ID: 22422245
    [No Abstract]   [Full Text] [Related]  

  • 3. The MATRICS consensus cognitive battery: what we know 6 years later.
    Green MF; Harris JG; Nuechterlein KH
    Am J Psychiatry; 2014 Nov; 171(11):1151-4. PubMed ID: 25756630
    [No Abstract]   [Full Text] [Related]  

  • 4. Next steps in clinical trial redesign.
    Nicholas J
    J Natl Cancer Inst; 2012 Jan; 104(2):90-2. PubMed ID: 22215851
    [No Abstract]   [Full Text] [Related]  

  • 5. The NIMH-MATRICS consensus statement on negative symptoms.
    Kirkpatrick B; Fenton WS; Carpenter WT; Marder SR
    Schizophr Bull; 2006 Apr; 32(2):214-9. PubMed ID: 16481659
    [No Abstract]   [Full Text] [Related]  

  • 6. NIMH Drug Trials for Schizophrenia.
    Torrey EF; Yolken RH; Lamb HR
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30677268
    [No Abstract]   [Full Text] [Related]  

  • 7. NIH rethinks psychiatry trials.
    Reardon S
    Nature; 2014 Mar; 507(7492):288. PubMed ID: 24646977
    [No Abstract]   [Full Text] [Related]  

  • 8. Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis.
    Schooler NR
    Br J Psychiatry Suppl; 1993 Dec; (22):58-65. PubMed ID: 7906525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The new paradigm: from 'bench to bedside' to the translational research 'valleys of death'.
    Tugwell P; Knottnerus JA
    J Clin Epidemiol; 2015 Jul; 68(7):725-6. PubMed ID: 26047303
    [No Abstract]   [Full Text] [Related]  

  • 10. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap.
    Pratt J; Winchester C; Dawson N; Morris B
    Nat Rev Drug Discov; 2012 Jun; 11(7):560-79. PubMed ID: 22722532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
    Cohen JD; Insel TR
    Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on "Translational applications of flow cytometry in clinical practice".
    Monneret G; Venet F
    J Immunol; 2012 Aug; 189(3):1099. PubMed ID: 22815377
    [No Abstract]   [Full Text] [Related]  

  • 13. The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment.
    Tai B; Straus MM; Liu D; Sparenborg S; Jackson R; McCarty D
    J Subst Abuse Treat; 2010 Jun; 38 Suppl 1(Suppl 1):S4-13. PubMed ID: 20307794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Important steps in the development of cognitive-enhancing drugs in schizophrenia.
    Buchanan RW
    Am J Psychiatry; 2006 Nov; 163(11):1867-9. PubMed ID: 17074932
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspective: Revealing molecular secrets.
    Hyman SE
    Nature; 2014 Apr; 508(7494):S20. PubMed ID: 24695333
    [No Abstract]   [Full Text] [Related]  

  • 16. American Society of Clinical Oncology Developing First Clinical Trial.
    Brower V
    J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
    [No Abstract]   [Full Text] [Related]  

  • 17. The Clinical Antipsychotic Trials of Intervention Effectiveness: what did we learn?
    Boyd MA
    Arch Psychiatr Nurs; 2008 Feb; 22(1):56-8. PubMed ID: 18207059
    [No Abstract]   [Full Text] [Related]  

  • 18. Personalized-medicine trials on the rise.
    Benowitz S
    J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
    [No Abstract]   [Full Text] [Related]  

  • 19. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
    Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion.
    J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.